StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) bonds

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$2.95−0.05 (-1.67%)

Close on Nov 17, 2026Market cap $268.41MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

SAB Biotherapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in SAB Biotherapeutics's 10-K for the period ended Dec 31, 2024

IssueCarrying value
8% Unsecured Convertible Note$0
Insurance Financing Note Payable$275.85K

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySize
Octobernote$542.00K

See a number that looks wrong?